These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29428459)

  • 1. Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.
    Dunn DT; Stöhr W; Arenas-Pinto A; Tostevin A; Mbisa JL; Paton NI;
    J Clin Virol; 2018 Apr; 101():63-65. PubMed ID: 29428459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
    Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
    Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.
    Paton NI; Stöhr W; Arenas-Pinto A; Fisher M; Williams I; Johnson M; Orkin C; Chen F; Lee V; Winston A; Gompels M; Fox J; Scott K; Dunn DT;
    Lancet HIV; 2015 Oct; 2(10):e417-26. PubMed ID: 26423649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
    Thompson JA; Kityo C; Dunn D; Hoppe A; Ndashimye E; Hakim J; Kambugu A; van Oosterhout JJ; Arribas J; Mugyenyi P; Walker AS; Paton NI;
    Clin Infect Dis; 2019 Mar; 68(7):1184-1192. PubMed ID: 30060027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.
    Fisher R; van Zyl GU; Travers SA; Kosakovsky Pond SL; Engelbrech S; Murrell B; Scheffler K; Smith D
    J Virol; 2012 Jun; 86(11):6231-7. PubMed ID: 22457522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
    Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
    AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
    Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
    Hoppe A; Giuliano M; Lugemwa A; Thompson JA; Floridia M; Walker AS; Senoga I; Abwola MC; Pirillo MF; Kityo CM; Arenas-Pinto A; Paton NI;
    Antivir Ther; 2018; 23(2):191-195. PubMed ID: 29021409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
    Descamps D; Lambert-Niclot S; Marcelin AG; Peytavin G; Roquebert B; Katlama C; Yeni P; Felices M; Calvez V; Brun-Vézinet F
    J Antimicrob Chemother; 2009 Mar; 63(3):585-92. PubMed ID: 19147519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors.
    Dalmat RR; Makhsous N; Pepper GG; Magaret A; Jerome KR; Wald A; Greninger AL
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30305383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
    Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
    McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
    Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.